Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer

von Minckwitz, Gϋnter; Procter, Marion; de Azambuja, Evandro; Zardavas, Dimitrios; Benyunes, Mark; Viale, Giuseppe; Suter, Thomas; Arahmani, Amal; Rouchet, Nathalie; Clark, Emma; Knott, Adam; Láng, István; Lévy, Christelle; A. Yardley, Denise; Bines, José; D. Gelber, Richard; Piccart, Martine; Baselga, José

doi:10.1056/nejmoa1703643

Public

Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer

Published in New England Journal of Medicine • Jun 5, 2017

Authors:

Gϋnter von Minckwitz

Marion Procter

Evandro de Azambuja

Abstract

BACKGROUND: Pertuzumab increases the rate of pathological complete response in the preoperative context and increases overall survival among patients with metastatic disease when it is added to trastuzumab and chemotherapy for the treatment of human epidermal growth factor receptor 2 (HER2)-positive...

Subject

Pertuzumab

Trastuzumab

Medicine

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!